CEREVEL THERAPEUTICS INVESTOR ALERT: Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Cerevel Therapeutics Holdings Investigation Launched by Bronstein, Gewirtz & Grossman, LLC

NEW YORK, April 25, 2023 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a leading law firm in the area of securities litigation, is investigating potential claims on behalf of investors who purchased or acquired Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) shares.

The investigation is focused on the company's potential violations of federal securities laws and whether certain statements made by Cerevel Therapeutics Holdings, Inc. during the relevant period were materially false and misleading.

The investigation is also focused on whether the company's officers and/or directors were aware of the foregoing and failed to disclose the information to investors, or whether they recklessly disregarded the information.

On April 22, 2023, the NASDAQ stock exchange halted trading in Cerevel Therapeutics Holdings, Inc. shares after the company announced that it would be delaying the filing of its quarterly report due to the ongoing investigation.

Investors who purchased or acquired Cerevel Therapeutics Holdings, Inc. shares are encouraged to contact Bronstein, Gewirtz & Grossman, LLC to discuss their legal rights and potential remedies. The investigation is ongoing and additional information will be released as it becomes available.

Contact: Bronstein, Gewirtz & Grossman, LLC, investorinfo@bgandg.com, 212-697-6484.